Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 16Thoracic 6Lymphoid 6Genitourinary 6Gastrointestinal 6Tumor-Agnostic 2Sarcoma 2Gynecologic 2Endocrine 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Head & Neck 1

Conditions

Somatostatinoma 1Pituitary Neoplasms 1Melanoma 1Growth Hormone-Secreting Pituitary Adenoma 1Carcinoma, Neuroendocrine 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
antineoplaston AS 2-1 × Dermatologic × Clear all
NCT00003509 2020-12-19

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

Burzynski Research Institute

Phase 2 Terminated
13 enrolled 5 charts
Dermatologic

Melanoma

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡